Recent Advances in the Search for Antiviral Agents Against Human Papillomaviruses

Overview

Journal Antivir Ther

Publisher Sage Publications

Specialties Infectious Diseases
Microbiology

Date 2007 Aug 3

PMID 17668552

Citations 14

Authors

Amelie Fradet-Turcotte

Jacques Archambault

Affiliations

Soon will be listed here.

Abstract

Infection by human papillomavirus (HPV) is extremely common and associated with the development of benign warts or malignant lesions of the skin and mucosa. Infection by a high-risk (oncogenic) anogenital HPV type, most often through sexual contacts, is the starting point of virtually all cases of cervical cancers and the majority of anal cancers. The same viral types are also increasingly being linked with a subset of head-and-neck and non-melanoma skin cancers. Although prophylactic vaccines are now available to protect against the four types most commonly found in cervical and anal cancers (HPV16 and HPV18) and anogenital warts (HPV6 and HPV11), these neither protect against all genital HPVs nor are of therapeutic utility for already infected patients. Thus, the need for antiviral agents to treat HPV-associated diseases remains great, but none currently exist. This article reviews the recent progress made towards the development of antiviral agents to treat HPV infections, from target identification and validation to the discovery of lead compounds with therapeutic potential. Emphasis has been placed on novel low-molecular-weight compounds that antagonize HPV proteins or, alternatively, inhibit cellular proteins which have been usurped by papillomaviruses and are mediating their pathogenic effects.

Citing Articles

C-71980262, a novel small molecule against human papilloma virus-16 E6 (HPV-16 E6) with anticancer potency against cervical cancer: A computational guided approach.

Kumar A Iran J Basic Med Sci. 2024; 27(11):1389-1396.

PMID: 39386235 PMC: 11459339. DOI: 10.22038/ijbms.2024.78090.16882.

Unveiling HPV's hidden link: Cardiovascular diseases and the viral intrigue.

Dutta P, Saha D, Earle M, Prasad C, Singh M, Darswal M Indian Heart J. 2024; 76(1):1-5.

PMID: 38387552 PMC: 10943540. DOI: 10.1016/j.ihj.2024.02.001.

Metabolic Profiling, Antiviral Activity and the Microbiome of Some Mauritian Soft Corals.

Jahajeeah D, Ranghoo-Sanmukhiya M, Schafer G Mar Drugs. 2023; 21(11).

PMID: 37999398 PMC: 10672535. DOI: 10.3390/md21110574.

Small Molecule Inhibitors of Human Papillomavirus: A Review of Research from 1997 to 2021.

Duncan C, Gunosewoyo H, Mocerino M, Payne A Curr Med Chem. 2023; 31(33):5308-5350.

PMID: 37448363 DOI: 10.2174/0929867331666230713165407.

The Reservoir of Persistent Human Papillomavirus Infection; Strategies for Elimination Using Anti-Viral Therapies.

Zheng K, Egawa N, Shiraz A, Katakuse M, Okamura M, Griffin H Viruses. 2022; 14(2).

PMID: 35215808 PMC: 8876702. DOI: 10.3390/v14020214.

References

Clad A, Gissmann L, Meier B, Freese U, Schwarz E . Molecular cloning and partial nucleotide sequence of human papillomavirus type 1a DNA. Virology. 1982; 118(1):254-9. DOI: 10.1016/0042-6822(82)90341-5. View

Lehman C, Botchan M . Segregation of viral plasmids depends on tethering to chromosomes and is regulated by phosphorylation. Proc Natl Acad Sci U S A. 1998; 95(8):4338-43. PMC: 22490. DOI: 10.1073/pnas.95.8.4338. View

Sanders C, Stenlund A . Recruitment and loading of the E1 initiator protein: an ATP-dependent process catalysed by a transcription factor. EMBO J. 1998; 17(23):7044-55. PMC: 1171052. DOI: 10.1093/emboj/17.23.7044. View

Meshnick S . Artemisinin: mechanisms of action, resistance and toxicity. Int J Parasitol. 2002; 32(13):1655-60. DOI: 10.1016/s0020-7519(02)00194-7. View

Abbate E, Voitenleitner C, Botchan M . Structure of the papillomavirus DNA-tethering complex E2:Brd4 and a peptide that ablates HPV chromosomal association. Mol Cell. 2006; 24(6):877-89. DOI: 10.1016/j.molcel.2006.11.002. View

Chang C, Heller J, Kuo J, Huang R . Tetra-O-methyl nordihydroguaiaretic acid induces growth arrest and cellular apoptosis by inhibiting Cdc2 and survivin expression. Proc Natl Acad Sci U S A. 2004; 101(36):13239-44. PMC: 516554. DOI: 10.1073/pnas.0405407101. View

Schweiger M, You J, Howley P . Bromodomain protein 4 mediates the papillomavirus E2 transcriptional activation function. J Virol. 2006; 80(9):4276-85. PMC: 1472042. DOI: 10.1128/JVI.80.9.4276-4285.2006. View

Brannon A, Maresca J, Boeke J, Basrai M, McBride A . Reconstitution of papillomavirus E2-mediated plasmid maintenance in Saccharomyces cerevisiae by the Brd4 bromodomain protein. Proc Natl Acad Sci U S A. 2005; 102(8):2998-3003. PMC: 549465. DOI: 10.1073/pnas.0407818102. View

Hoessel R, Leclerc S, Endicott J, Nobel M, Lawrie A, Tunnah P . Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases. Nat Cell Biol. 1999; 1(1):60-7. DOI: 10.1038/9035. View

10.

Rocque W, Porter D, Barnes J, Dixon E, Lobe D, Su J . Replication-associated activities of purified human papillomavirus type 11 E1 helicase. Protein Expr Purif. 2000; 18(2):148-59. DOI: 10.1006/prep.1999.1182. View

11.

Suzuki T, Matsuura A, Kouketsu A, Nakagawa H, Miyata N . Identification of a potent non-hydroxamate histone deacetylase inhibitor by mechanism-based drug design. Bioorg Med Chem Lett. 2004; 15(2):331-5. DOI: 10.1016/j.bmcl.2004.10.074. View

12.

Chan S, Delius H, Halpern A, Bernard H . Analysis of genomic sequences of 95 papillomavirus types: uniting typing, phylogeny, and taxonomy. J Virol. 1995; 69(5):3074-83. PMC: 189008. DOI: 10.1128/JVI.69.5.3074-3083.1995. View

13.

Hegde R . The papillomavirus E2 proteins: structure, function, and biology. Annu Rev Biophys Biomol Struct. 2002; 31:343-60. DOI: 10.1146/annurev.biophys.31.100901.142129. View

14.

He W, Staples D, Smith C, Fisher C . Direct activation of cyclin-dependent kinase 2 by human papillomavirus E7. J Virol. 2003; 77(19):10566-74. PMC: 228519. DOI: 10.1128/jvi.77.19.10566-10574.2003. View

15.

Nguyen M, Nguyen M, Caruana G, Bernstein A, Lambert P, Griep A . Requirement of PDZ-containing proteins for cell cycle regulation and differentiation in the mouse lens epithelium. Mol Cell Biol. 2003; 23(24):8970-81. PMC: 309609. DOI: 10.1128/MCB.23.24.8970-8981.2003. View

16.

Thomas J, Hubert W, Ruesch M, Laimins L . Human papillomavirus type 31 oncoproteins E6 and E7 are required for the maintenance of episomes during the viral life cycle in normal human keratinocytes. Proc Natl Acad Sci U S A. 1999; 96(15):8449-54. PMC: 17536. DOI: 10.1073/pnas.96.15.8449. View

17.

Berg M, Stenlund A . Functional interactions between papillomavirus E1 and E2 proteins. J Virol. 1997; 71(5):3853-63. PMC: 191536. DOI: 10.1128/JVI.71.5.3853-3863.1997. View

18.

Duensing S, Lee L, Duensing A, Basile J, Piboonniyom S, Gonzalez S . The human papillomavirus type 16 E6 and E7 oncoproteins cooperate to induce mitotic defects and genomic instability by uncoupling centrosome duplication from the cell division cycle. Proc Natl Acad Sci U S A. 2000; 97(18):10002-7. PMC: 27652. DOI: 10.1073/pnas.170093297. View

19.

McPhillips M, Ozato K, McBride A . Interaction of bovine papillomavirus E2 protein with Brd4 stabilizes its association with chromatin. J Virol. 2005; 79(14):8920-32. PMC: 1168793. DOI: 10.1128/JVI.79.14.8920-8932.2005. View

20.

Davidson W, McGibbon G, White P, Yoakim C, Hopkins J, Guse I . Characterization of the binding site for inhibitors of the HPV11 E1-E2 protein interaction on the E2 transactivation domain by photoaffinity labeling and mass spectrometry. Anal Chem. 2004; 76(7):2095-102. DOI: 10.1021/ac035335o. View